

**To:** Breneman, Sara[breneman.sara@epa.gov]; Smith, Molly[Smith.Molly@epa.gov]; Miller, Patrick[miller.patrick@epa.gov]; Marshall, Sarah[marshall.sarah@epa.gov]  
**From:** Cantello, Nicole  
**Sent:** Thur 10/5/2017 9:51:57 PM  
**Subject:** FW: ATSDR Statement regarding the use of the ATSDR Chronic MRL

I would like to have a discussion regarding derailing this suggestion.

Best,

Nicole Cantello

Attorney/Advisor

U.S. Environmental Protection Agency

77 West Jackson Boulevard

Chicago, Illinois 60604

312/886-2870

cantello.nicole@epa.gov

*This message and any attachments may contain confidential information protected by the attorney-client, attorney work product or other privilege. If you believe that it has been sent to you in error, please reply to the sender that you received the message in error. Then delete it. Thank you.*

**From:** Bollweg, George  
**Sent:** Thursday, October 05, 2017 4:20 PM  
**To:** Smith, Molly <Smith.Molly@epa.gov>; Nam, Ed <nam.ed@epa.gov>; Breneman, Sara <breneman.sara@epa.gov>; Marshall, Sarah <marshall.sarah@epa.gov>; Miller, Patrick <miller.patrick@epa.gov>  
**Cc:** Cain, Alexis <cain.alexis@epa.gov>; Siegel, Kathryn <siegel.kathryn@epa.gov>; Furey, Eileen <furey.eileen@epa.gov>; Cantello, Nicole <cantello.nicole@epa.gov>  
**Subject:** RE: ATSDR Statement regarding the use of the ATSDR Chronic MRL

Because OAQPS is a primary US EPA advocate for risk assessment use of ATSDR's chronic Mn inhalation MRL, we should consider asking them for their take on this.

**From:** Smith, Molly

**Sent:** Thursday, October 05, 2017 3:44 PM

**To:** Nam, Ed <[nam.ed@epa.gov](mailto:nam.ed@epa.gov)>; Breneman, Sara <[breneman.sara@epa.gov](mailto:breneman.sara@epa.gov)>; Marshall, Sarah <[marshall.sarah@epa.gov](mailto:marshall.sarah@epa.gov)>; Miller, Patrick <[miller.patrick@epa.gov](mailto:miller.patrick@epa.gov)>

**Cc:** Bollweg, George <[bollweg.george@epa.gov](mailto:bollweg.george@epa.gov)>; Cain, Alexis <[cain.alexis@epa.gov](mailto:cain.alexis@epa.gov)>; Siegel, Kathryn <[siegel.kathryn@epa.gov](mailto:siegel.kathryn@epa.gov)>; Furey, Eileen <[furey.eileen@epa.gov](mailto:furey.eileen@epa.gov)>; Cantello, Nicole <[cantello.nicole@epa.gov](mailto:cantello.nicole@epa.gov)>

**Subject:** RE: ATSDR Statement regarding the use of the ATSDR Chronic MRL

Ed –

In an October 2, 2017, correspondence from the company they confirmed the August monthly average for Mn to be 0.197 ug/m<sup>3</sup>, bringing the cumulative average to 0.29 ug/m<sup>3</sup>. However, the data has not been submitted to us.

Is this the final statement we are expecting before ATSDR before they put out their health consultation? Will this position be formalized in any document or should we be citing this email? I am not aware of any other statements.

Molly Smith

Environmental Scientist

U.S. EPA Region 5

Air Enforcement and Compliance Assurance

Phone: (312) 353-8773

Fax: (312) 697-2724

*This message and any attachments may contain confidential information protected by the attorney-client or other privilege. If you believe that it has been sent to you in error, please reply to the sender. Then delete it. Thank you.*

**From:** Nam, Ed

**Sent:** Thursday, October 05, 2017 3:34 PM

**To:** Breneman, Sara <[breneman.sara@epa.gov](mailto:breneman.sara@epa.gov)>; Marshall, Sarah <[marshall.sarah@epa.gov](mailto:marshall.sarah@epa.gov)>; Miller, Patrick <[miller.patrick@epa.gov](mailto:miller.patrick@epa.gov)>

**Cc:** Smith, Molly <[Smith.Molly@epa.gov](mailto:Smith.Molly@epa.gov)>; Bollweg, George <[bollweg.george@epa.gov](mailto:bollweg.george@epa.gov)>; Cain, Alexis <[cain.alexis@epa.gov](mailto:cain.alexis@epa.gov)>; Siegel, Kathryn <[siegel.kathryn@epa.gov](mailto:siegel.kathryn@epa.gov)>; Furey, Eileen <[furey.eileen@epa.gov](mailto:furey.eileen@epa.gov)>

**Subject:** RE: ATSDR Statement regarding the use of the ATSDR Chronic MRL

This looks good to me. Any questions?

Did DCHI already put out a statement?

Molly, what was the measurement for August? Do we have the data yet?

-Ed

**From:** Johnson, Mark

**Sent:** Thursday, October 05, 2017 3:30 PM

**To:** Nam, Ed <[nam.ed@epa.gov](mailto:nam.ed@epa.gov)>; Breneman, Sara <[breneman.sara@epa.gov](mailto:breneman.sara@epa.gov)>; Marshall, Sarah <[marshall.sarah@epa.gov](mailto:marshall.sarah@epa.gov)>; Miller, Patrick <[miller.patrick@epa.gov](mailto:miller.patrick@epa.gov)>

**Cc:** Colledge, Michelle (ATSDR/DCHI/CB) <[mna9@cdc.gov](mailto:mna9@cdc.gov)>; Smith, Molly <[Smith.Molly@epa.gov](mailto:Smith.Molly@epa.gov)>

**Subject:** ATSDR Statement regarding the use of the ATSDR Chronic MRL

Ed

While we are preparing a review of the air monitoring data for the SH Bell facility in SE

Chicago, we wanted to communicate a clear statement regarding the use of the ATSDR Chronic Inhalation MRL for manganese:

The Agency for Toxic Substances and Disease Registry's Division of Toxicology and Human Health Studies concurs with DCHI that it is appropriate to use the Chronic Inhalation MRL for manganese to evaluate the public health implications of environmental exposures to manganese over a period as short as 3 months.

Let me know if you have any questions regarding this statement or our policies.

Mark

---

Mark D. Johnson, PhD, DABT

Regional Director/Toxicologist

Agency for Toxic Substances and Disease Registry (ATSDR)

77 W. Jackson Blvd.

Chicago, IL 60604

Office: 312-353-3436

Email: [mdjohnson@cdc.gov](mailto:mdjohnson@cdc.gov)